key: cord-1013890-pnf3rlx2 authors: Attwood, Lucy O; Francis, Michelle J; Hamblin, John; Korman, Tony M; Druce, Julian; Graham, Maryza title: Clinical evaluation of AusDiagnostics SARS-CoV-2 multiplex tandem PCR assay date: 2020-05-19 journal: J Clin Virol DOI: 10.1016/j.jcv.2020.104448 sha: c37c4901718df681dc62092062476b4c4f13db2d doc_id: 1013890 cord_uid: pnf3rlx2 BACKGROUND: In the context of the pandemic, the rapid emergency use authorisation of diagnostic assays for SARS-CoV-2 has meant there are few peer-reviewed published studies of clinical performance of commercial assays. AIMS: To evaluate the clinical performance of AusDiagnostics respiratory multiplex tandem PCR assay including SARS-CoV-2. METHODS: We reviewed the results following implementation of AusDiagnostics respiratory multiplex tandem PCR assay including SARS-CoV-2, and compared with an in-house RT-PCR assay at our State Reference Laboratory. RESULTS: Initial validation using AusDiagnostics coronavirus multiplex tandem PCR assay including SARS-CoV-2 demonstrated good concordance with the State Reference Laboratory. After implementing the AusDiagnostics respiratory multiplex tandem PCR assay including SARS-CoV-2, we tested 7,839 samples. 127 samples in which SARS-CoV-2 was detected using the AusDiagnostics assay were referred for testing at the State Reference Laboratory, with concordant results in 118/127 (92.9%) of samples. After resolution of discrepancies, 125/127 (98.4%) of AusDiagnostics results were determined to be true positive results. Out of 7,839 samples tested for SARS-CoV-2 during this period, only 2 tests (0.02%) were indeterminate results. CONCLUSION: The AusDiagnostics respiratory MT-PCR assay is a reliable assay for detection of SARS-CoV-2. In December 2019, a novel strain of coronavirus, severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), was recognized in Hubei Province, China (1) (2) (3) . This rapidly spread throughout other countries and was subsequently declared a pandemic by the World Health Organisation (WHO) in March 2020 (4) . The symptoms expressed by COVID-19 patients are non-specific and cannot be used alone for an accurate diagnosis. These symptoms include fever, cough, fatigue, sputum production and shortness of breath, all of which can be associated with many other respiratory infections (5) . Accurate and rapid diagnostics is crucial for clinical management and to allow for epidemiological tracking and rapid implementation of control measures that limit the spread of SARS-CoV-2 through case identification, isolation and contact tracing. commercial nucleic acid amplification diagnostic assays (9, 10) . However, few large evaluations of clinical performance of these commercial assays have been published (11) (12) (13) . Respiratory multiplex PCR testing is an established method for diagnosis of respiratory viral infections. Our laboratory was using the AusDiagnostics Respiratory multiplex PCR, which has comparable performance to other commercial and inhouse RT-PCR assays for detection of non-SARS-CoV-2 pathogens (14) (15) (16) . Rapid commencement of testing for SARS-CoV-2 was required in response to the COVID-19 pandemic. The first reported case of COVID-19 in Australia presented to our health service on 24 January 2020 and SARS-CoV-2 was detected by RT-PCR at the Victorian Infectious Diseases Reference Laboratory (18) . Integration of SARS-CoV-2 testing as part of routine respiratory multiplex PCR testing was our preferred strategy for SARS-CoV-2 diagnosis. AusDiagnostics developed a molecular diagnostic test to detect SARS-CoV-2 and the assay received European CE marking and Australian Therapeutic Goods Administration registration in March 2020. (9, 17) This study evaluated the AusDiagnostics Respiratory multiplex tandem PCR (14, 15) including SARS-CoV-2 and compared results to an in-house real-time TaqMan PCR at our State Reference Laboratory (18) . Our laboratory services Monash Health, a large metropolitan health care network in Melbourne, Australia with 2,150 inpatient beds, three emergency J o u r n a l P r e -p r o o f departments and four community respiratory assessment clinics that opened in response to the COVID-19 pandemic. Combined oropharyngeal and nasopharyngeal swabs were collected according to national guidelines (19) using FLOQSwabs ® and transported in UTM medium (Copan, Brescia, Italy). Sputum and endotracheal aspirates were also accepted for testing for suspected SARS-CoV-2. Samples were stored at 4˚C before processing. AusDiagnostics (Mascot, Australia) tests utilise a multiplex-tandem polymerase chain reaction (MT-PCR). The assays consist of two amplification steps where the primary amplification involves "target enrichment" using target-specific outer primer sets with a small number of PCR cycles, followed by secondary amplification where inner primers amplify a target region within the product from the primary amplification. Extraction occurred on AusDiagnostics MT-Prep extraction system as per manufacturer's instructions. Results discordant between the two assays were further assessed by analysing results from other specimens from the same patient. Amplicons generated from discordant samples were referred to AusDiagnostics for pyrosequencing. All samples from patients that had SARS-CoV-2 detected by more than one assay from any sample or by pyrosequencing were determined to be true positive results. A sample from a patient that was positive by only one RT-PCR assay and had no specific product detected by pyrosequencing was determined to be an indeterminate result if no other samples from that patient were determined to be a true positive result. In our initial validation of the AusDiagnostics MT-PCR including SARS-CoV-2, we did not detect SARS-CoV-2 in 59 of 60 (98.3%) samples were negative for SARS-CoV-2 at the reference laboratory. The one discordant sample was from a J o u r n a l P r e -p r o o f patient with characteristic clinical and radiological features of COVID-19 who had returned from travel in Iran. SARS-CoV-2 was detected at the reference laboratory from a repeat specimen collected the following day. (See Table 1 , Patient A.) The AusDiagnostics assay including the SARS-CoV-2 target achieved 100% concordance of results using the proficiency-testing panel with blinded samples. Following the initial validation, the AusDiagnostics Respiratory Pathogens multiplex assay including SARS-CoV-2 was implemented and 7,839 samples were tested during the one-month study period. Table 1 summarises the nine discordant results during the study period. Two of these tests were repeat swabs for health care workers undergoing clearance swabs to return to work (patients 8 & 9). They both subsequently had a further positive test on repeat swabs at the reference laboratory and therefore were classified as true positive results. Pyrosequencing demonstrated that five out of the nine discordant results were positive for SARS-CoV-2 RNA (patients 1, 3, 4, 5 and 6.) Therefore, seven of nine (77.8%) discordant results were classified as true positives. Two patients were classified as having indeterminate results as there was insufficient amplicon for pyrosequencing and no further positive samples. Thus, only two of 7,839 (0.02%) samples tested for SARS-CoV-2 were indeterminate results. Laboratories have been required to implement new testing platforms rapidly to respond to the SARS-CoV-2 public health crisis. This study demonstrates that the AusDiagnostics MT-PCR assay is a reliable assay for detection of SARS-CoV-2 with a high level of correlation with the reference laboratory in-house RT-PCR. The AusDiagnostics multiplex assay performed well when rapidly implemented in a busy hospital laboratory, also allowing the benefit of detection of other respiratory pathogens. This is the largest study of a non-manufacturer sponsored review of a commercial assay for SARS-CoV-2 and supports its use in this pandemic (13, (21) (22) (23) . results. This includes RNA degradation (for example, during transport or storage between the two assays being performed), differences in genetic targets, primer sequences, reagents, or amplification conditions. The two assays target different SARS-CoV-2-specific genes, which could lead to false negative results if a mutation prevents primer binding. Natural variability at the limit of detection of PCR assays may also be explained by sampling differences. Several of the samples in our study were from patients having clearance swabs collected at least a week after symptom J o u r n a l P r e -p r o o f onset, thus the viral load would be expected to be at or near the limit of detection for many of these samples. As with all nucleic acid amplification assays there is the possibility of contamination and this may explain the two samples with indeterminate results since these were both detected at low level and not confirmed on repeat testing. In particular one patient (patient 7) had no clear epidemiological risk factors for SARS-CoV-2 and the virus was not detected in two other specimens from this patient, however there were no other positive patient samples on the initial runs that included these two patient's indeterminate results. The large number of clinical specimens tested (7,839) with only two potential false positive samples indicates high specificity of the AusDiagnostics assay. A pneumonia outbreak associated with a new coronavirus of probable bat origin Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study The emergence of a novel coronavirus (SARS-CoV-2), their biology and therapeutic options WHO Director-General's opening remarks at the media briefing on Clinical Characteristics of Coronavirus Disease 2019 in China CDNA National guidelines for public health units Diagnostic detection of 2019-nCoV by real-time RT-PCR. Berlin2020 Comparative Performance of SARS-CoV-2 Detection Assays using Seven Different Primer/Probe Sets and One Assay Kit COVID-19 test kits included on the ARTG for legal supply in Australia; Australian Government Department of Health Therapeutic Goods Administration Rapid random access detection of the novel SARS-coronavirus-2 (SARS-CoV-2, previously 2019-nCoV) using an open access protocol for the Panther Fusion The Detection of SARS-CoV-2 using the Cepheid Xpert Xpress SARS-CoV-2 and Roche cobas SARS-CoV-2 Assays Comparison of four multiplex PCR assays for the detection of viral pathogens in respiratory specimens Comparison of a rapid antigen test with nucleic acid testing during cocirculation of pandemic influenza A/H1N1 2009 and seasonal influenza A/H3N2 Respiratory virus detection and co-infection in children and adults in a large Australian AusDiagnostics gets CE mark for multiplex coronavirus, flu Isolation and rapid sharing of the 2019 novel coronavirus (SARS-CoV-2) from the first patient diagnosed with COVID-19 in Australia COVID-19); Series of National Guidelines (SoNGs) CDNA National guidelines for public health units 2020 Clinical evaluation of the cobas SARS-CoV-2 test and a diagnostic platform switch during 48 hours in the midst of the COVID-19 pandemic Diasorin Simplexa, and CDC FDA EUA methods for the detection of SARS-CoV-2 from nasopharyngeal and nasal swabs from individuals diagnosed with COVID-19 Comparison of Copan Eswab and FLOQswab for COVID-19 PCR diagnosis: working around AusDiagnostics for facilitating pyrosequencing results on discordant samples.Microbiology laboratory staff at Monash Health.